Aclaris Therapeutics Inc

NASDAQ:ACRS  
12.08
+0.05 (+0.42%)
Earnings Announcements

Aclaris Therapeutics Reports First Quarter 2022 Financial Results And Provides A Corporate Update

Published: 05/10/2022 11:38 GMT
Aclaris Therapeutics Inc (ACRS) - Aclaris Therapeutics Reports First Quarter 2022 Financial Results and Provides a Corporate Update.
Q1 Revenue $1.5 Million.
April Capital Raise Extends Cash Runway Through End of 2025.
Clinical Sites Activated for Phase 2b Trial of Ati-1777.
Qtrly Loss per Share $0.31.
Q1 Earnings per Share View $-0.40, Revenue View $1.7 Million -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $1.66 Million
Adjusted EPS is expected to be -$0.37

Next Quarter Revenue Guidance is expected to be $1.66 Million
Next Quarter EPS Guidance is expected to be -$0.40

More details on our Analysts Page.